Pomegra
Tempus AI Stock Jumps 12% After Q3 Earnings Beat
Why did Tempus AI stock jump 12%?
Tempus AI (TEM) stock rose about 12% on Monday to $83.26 after third-quarter revenue grew 23% to $411.5M and beat estimates, with adjusted EBITDA also ahead of forecasts.
Key numbers
| Q3 revenue | $411.5M+23% YoY (about $409M expected) |
|---|---|
| Adjusted EBITDA | $25.6Mvs $1.5M a year earlier |
| Stock move on Monday | $83.26+12.07% (per [3]) |
| 2026 revenue guidance | $1.60–1.605Bfrom $1.595–1.605B prior |
| Net loss | $14.9Mvs $80.0M a year earlier |
What happened
Tempus AI (TEM) stock rose about 12% on Monday to $83.26 after third-quarter revenue grew 23% to $411.5M and beat estimates, with adjusted EBITDA also ahead of forecasts. Tempus sells genetic tests that help doctors choose cancer treatments, and it also licenses its patient data to drug companies. Analysts had expected about $409 million in sales. Adjusted EBITDA, a measure of operating profit that leaves out some costs, was $25.6 million, up from $1.5 million a year earlier. The company also raised its full-year sales forecast to $1.60–$1.605 billion.
Why it matters
Tempus AI uses artificial intelligence to analyze genetic and cancer data, and this report shows its sales are still growing fast while its profits improve. Adjusted EBITDA was $25.6 million, up from $1.5 million a year earlier, and the company expects about $65 million for the full year. It suggests the business is moving toward earning money steadily, though it still reported a net loss of $14.9 million for the quarter.
Who this affects
- MarketbullishLow impact
- Investors in AI-linked healthcare stocks get a positive earnings signal.
- CompanybullishHigh impact
- Shareholders gain as sales beat and the full-year forecast rises.
- CompetitorsmixedLow impact
- Rivals like Guardant and Natera face a fast-growing peer.
- IndustrybullishMedium impact
- Cancer-testing and health-data firms see continued strong demand.
Tempus AI vs Guardant Health, Natera
How we got here
Tempus reports Q2 revenue of $382.5M, up 22% from a year earlier.
Tempus reports Q3 revenue of $411.5M and raises its 2026 revenue forecast.
Shares climb about 12% to $83.26 in late-afternoon trading.
What to watch
- Company expects Q4 revenue of $458–463M and adjusted EBITDA of about $34M.Q4 2026
- Tempus shareholder meeting on its planned Personalis acquisition.2026-11-30
- Peer Guardant Health reports Q3 results, a read-across for cancer-testing demand.2026-11-05
Educational content only. Not investment advice.
More briefsAll briefs →
IDEXX Stock Jumps 20% After Q3 Earnings Beat
IDEXX (IDXX) raised its 2026 profit outlook as demand for pet blood and lab tests grew 11% in the quarter.
No new Xi visit to the White House this Thursday; the next Trump–Xi meeting is expected at APEC in Shenzhen
Xi's White House state visit was on 24 September. The trade truce now runs to 10 January 2027, and the leaders are expected to meet again on 18–19 November.
Dow Rises 0.4% as Nasdaq Falls 1.1% in Tech Rotation
Sherwin-Williams (SHW) rose 5.9% and Home Depot (HD) 3.6% as investors moved money out of AI-heavy tech.